Signaling bias in drug discovery

References

• Kenakin TP, Ambrose JR, Irving PE. The relative efficiency of beta adrenoceptor coupling to myocardial inotropy and diastolic relaxation: organ-selective treatment for diastolic dysfunction. J Pharmacol Exp Ther. 1991;257:1189–1197. ​​​​
   PubMed Web of Science ®Google Scholar
• Roth BL, Chuang DM. Multiple mechanisms of serotonergic signal transduction. Life Sci. 1987;41:1051–1064.
   PubMed Web of Science ®Google Scholar
• Kenakin TP, Morgan PH. Theoretical effects of single and multiple transducer receptor coupling proteins on estimates of the relative potency of agonists. Mol Pharmacol. 1989;35:214–222.
   PubMed Web of Science ®Google Scholar
• Freire E. Statistical thermodynamic linkage between conformational and binding equilibria. Adv Protein Chem. 1998;51:255–279.
   PubMedGoogle Scholar
• Frauenfelder H, Sligar SG, Wolynes PG. The energy landscapes and motions of proteins. Science. 1991;254:1598–1603.
   PubMed Web of Science ®Google Scholar
• Hilser VJ, Dowdy D, Oas TG, et al. The structural distribution of cooperative interactions in proteins: analysis of the native state ensemble. Proc Natl Acad Sci USA. 1998;95:9903–9908.
   PubMed Web of Science ®Google Scholar
• Hilser VJ, García-Moreno EB, Oas TG, et al. A statistical thermodynamic model of the protein ensemble. Chem Rev. 2006;106:1545–1558.
   PubMed Web of Science ®Google Scholar
• Hilser VJ, Thompson EB. Intrinsic disorder as a mechanism to optimizeallosteric coupling in proteins. Proc Natl Acad Sci USA. 2007;104:8311–8315.
   PubMed Web of Science ®Google Scholar
• Onaran HO, Costa T. Agonist efficacy and allosteric models of receptor action. Ann N Y Acad Sci. 1997;812:98–115.
   PubMed Web of Science ®Google Scholar
• Onaran HO, Scheer A, Cotecchia S, et al. A look at receptor efficacy. From the signaling network of the cell to the intramolecular motion of the receptor,in the pharmacology of functional, biochemical, and recombinant systems (handbook of experimental pharmacology). Kenakin TP, Angus JA, eds. Vol. 148:217–280. Heidelberg, Germany: Springer; 2000.
   Google Scholar
• Hermans E. Biochemical and pharmacological control of the multiplicity of coupling at G-protein-coupled receptors. Pharmacol Ther. 2003;99:25–44.
   PubMed Web of Science ®Google Scholar
• Laugwitz K-L, Allgeier A, Offermanns S, et al. The human thyrotropic receptor: a heptahelical receptor capable of stimulating members of all four G protein families. Proc Natl Acad Sci USA. 1996;93:116–120.
   PubMed Web of Science ®Google Scholar
• Spengler D, Waeber C, Pantaloni C, et al. Differential signal transduction by five splice variants of the PACAP receptor. Nature. 1993;365:170–175.
   PubMed Web of Science ®Google Scholar
• Kenakin T. Agonist-receptor efficacy. II. Agonist trafficking of receptor signals. Trends Pharmacol Sci. 1995;16:232–238.
   PubMed Web of Science ®Google Scholar
• Jarpe MB, Knall C, Mitchell FM, et al. [D-Arg1, D-Phe5,D-Trp7,9,Leu11]Substance P acts as a biased agonist toward neuropeptide and chemokine receptors. J Biol Chem. 1998;273:3097–3104.
   PubMed Web of Science ®Google Scholar
• Lawler CP, Prioleau C, Lewis MM, et al. Interactions of the novel antipsychotic aripiprazole(OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology. 1999;20:612–627.
   PubMed Web of Science ®Google Scholar
• Kenakin T. New concepts in drug discovery: collateral efficacy and permissive antagonism. Nat Rev Drug Discov. 2005;4:919–927.
   PubMed Web of Science ®Google Scholar
• Jl W, Von Zastrow M. Dissociation of functional roles of dynamin in receptor-mediated endocytosis and mitogenic signal transduction. J Biol Chem. 1999;274:24575–24578.
   PubMed Web of Science ®Google Scholar
• Kudlacek O, Waldhoer M, Kassack MU, et al. Biased inhibition by a suramin analogue of A1-adenosine eceptor/G protein coupling in fused receptor/G protein tandems: the A1-adenosine receptor is predominantly coupled to Go-alpha in human brain. Naunyn Schmiedebergs Arch Pharmacol. 2002;365:8–16.
   PubMed Web of Science ®Google Scholar
• Manning DR. Measures of efficacy using G proteins as endpoints: differential engagement of G proteins through single receptors. Mol Pharmacol. 2002;62:451–452.
   PubMed Web of Science ®Google Scholar
• Gonzalez E, Kulkarni H, Bolivar H, et al. The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. Science. 2005;307:1434–1440.
   PubMed Web of Science ®Google Scholar
• Muniz-Medina VM, Jones S, Maglich JM, et al. The relative activity of “function sparing” HIV-1 entry inhibitors on viral entry and CCR5 internalization: is allosteric functional selectivity a valuable therapeutic property? Mol Pharmacol. 2009;75:490–501.
   PubMed Web of Science ®Google Scholar
• Kenakin T, Watson C, Muniz-Medina V, et al. A simple method for quantifying functional selectivity and agonist bias. ACS Chem Neurosci. 2012;3:193–203.
   PubMed Web of Science ®Google Scholar
• Ferrari SL, Pierroz DD, Glatt V, et al. Bone response to intermittent parathyroid hormone is altered in mice null for β-Arrestin2. Endocrinology. 2005;146:1854–1862.
   PubMed Web of Science ®Google Scholar
• Gesty-Palmer D, Chen M, Reiter E, et al. Distinct beta-arrestin- and G protein-dependent pathways for parathyroid hormone receptor-stimulated ERK1/2 activation. J Biol Chem. 2006;281:10856–10864.
   PubMed Web of Science ®Google Scholar
• Gesty-Palmer D, Flannery P, Yuan L, et al. A b-arrestin-biased agonist of the parathyroid hormone receptor (PTH1R) promotes bone formation independent of G protein activation. Sci Transl Med. 2009;1:1ra1.
   PubMed Web of Science ®Google Scholar
• Sonoda N, Imamura T, Yoshizaki T, et al. β-Arrestin-1 mediates glucagon-like peptide-1 signaling to insulin secretion in cultured pancreatic b cells. Proc Natl Acad Sci USA. 2008;105:6614–6619.
   PubMed Web of Science ®Google Scholar
• Raehal KM, Walker JK, Bohn LM. Morphine side effects in beta-arrestin 2 knockout mice. J Pharmacol Exp Ther. 2005;314:1195–1201.
   PubMed Web of Science ®Google Scholar
• DeWire SM, Yamashita DS, Rominger DH, et al. A G protein-biased ligand at the μ-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine. J Pharmacol Exp Ther. 2013;344:708–717.
   PubMed Web of Science ®Google Scholar
• White KL, Scopton AP, Rives M-L, et al. Identification of novel functionally selective k-opioid receptor scaffolds. Mol Pharmacol. 2014;85:83–90.
   PubMed Web of Science ®Google Scholar
• Violin JD, Dewire SM, Barnes WG, et al. G protein-coupled receptor kinase and beta-arrestin-mediated desensitization of the angiotensin II type 1A receptor elucidated by diacylglycerol dynamics. J Biol Chem. 2006;281:36411–36419.
   PubMed Web of Science ®Google Scholar
• Violin JD, DeWire SM, Yamashita D, et al. Selectively engaging β-arrestins at the angiotensin II type 1 receptor reduces blood pressure and increases cardiac performance. J Pharmacol Exp Ther. 2010;335:572–579.
   PubMed Web of Science ®Google Scholar
• Watson C, Chen G, Irving P, et al. The use of stimulus-biased assay systems to detect agonist-specific receptor active states: implications for the trafficking of receptor stimulus by agonists. Mol Pharmacol. 2000;58:1230–1238.
   PubMed Web of Science ®Google Scholar
• Chen G, Way J, Armour S, et al. Use of constitutive G protein-coupled receptor activity for drug discovery. Mol Pharmacol. 2000;57:125–134.
   PubMed Web of Science ®Google Scholar
• Christmanson L, Westermark P, Betsholtz C. Islet amyloid polypeptide stimulates cyclic AMP accumulation via the porcine calcitonin receptor. Biochem Biophys Res Commun. 1994;205:1226–1235.
   PubMed Web of Science ®Google Scholar
• Felker M, Butler J, Collins S et al.: Biased ligand of the angiotensin receptor in acute heart failure (BLAST-AHF) Presented to the Heart Failure Association of the ESC, Florence Italy 2016: http://www.trevena.com/pdf/Phase2bBLAST-AHFdata.pdf
   Google Scholar
• Black JW, Leff P. Operational models of pharmacological agonism. Proc R Soc Lond B Biol Sci. 1983;220:141–162.
   PubMed Web of Science ®Google Scholar
• Black JW, Leff P, Shankley NP, et al. An operational model of pharmacological agonism: the effect of E/[A] curve shape on agonist dissociation constant estimation. Br J Pharmacol. 1985;84:561–571.
   PubMed Web of Science ®Google Scholar
• Kenakin T. New concepts in pharmacological efficacy at 7TM receptors: IUPHAR review 2. Br J Pharmacol 168. 2013;168:554–575. ​​​​
   PubMed Web of Science ®Google Scholar
• Kenakin TP. The effective application of biased signaling to new drug discovery. Mol Pharmacol. 2015;88:1055–1061.
   PubMed Web of Science ®Google Scholar
• Stahl EL, Zhou L, Ehlert FJ, et al. A novel method for analyzing extremely biased agonism at G protein–coupled receptors. Mol Pharmacol. 2015;87:866–877.
   PubMed Web of Science ®Google Scholar
• Unett DJ, Gatlin J, Anthony TL, et al. Kinetics of 5-HT2B receptor signaling: profound agonist-dependent effects on signaling onset and duration. J Pharmacol Exp Ther. 2013;347:645–659.
   PubMed Web of Science ®Google Scholar
• Herrenbrink CK, Sykes DA, Donthamsetti P, et al. The role of kinetic context in apparent biased agonism at GPCRs Nature Commun. DOI:10.1038/ncomms10842
   Google Scholar
• Rasmussen,S.G.F., DeVree, B.T., Zou,Y., Kruse, A.C., Chung, K.Y., Kobilka, T.S., et al. (2011a) Crystal structure of the β2 adrenergic receptor–Gs protein complex. Nature 477: 549–555.
   Google Scholar
• Rasmussen SGF, Choi H-J, Fung JJ, et al. Structure of a nanobody-stabilized active state of the β2 adrenoceptor. Nature. 2011b;469:175–180.
   PubMed Web of Science ®Google Scholar
• Kruse AC, Ring AM, Manglik A, et al. Activation and allosteric modulatiojn of a muscarinic acetylcholine receptor. Nature. 2013;504:101–106.
   PubMed Web of Science ®Google Scholar
• Mary S, Damian M, Louet M, et al. Ligands and signaling proteins govern the conformational landscape explored by a G protein-coupled receptor. Proc Natl Acad Sci USA. 2012;109:8304–8309.
   PubMed Web of Science ®Google Scholar
• Yan F, Mosier PD, Westkaemper RB, et al. Gα-Subunits differentially alter the conformation and agonist affinity of κ-opioid receptors. Biochem. 2008;47:1567–1578.
   PubMed Web of Science ®Google Scholar
• Kenakin TP. What is pharmacological ‘affinity’? Relevance to biased agonism and antagonism. Trends Pharmacol Sci. 2014;35:434–441.
   PubMed Web of Science ®Google Scholar
• Strachan RT, Sciaky N, Cronan MR, et al. Genetic deletion of p90 ribosomal s6 kinase 2 alters patterns of 5-Hydroxytryptamine2A serotonin receptor functional selectivity. Mol Pharmacol. 2010;77:327–338.
   PubMed Web of Science ®Google Scholar
• Nijmeijer S, Vischer HF, Rosethorne EM, et al. Analysis of multiple histamine H4 receptor compound classes uncovers Gαi protein- and β-Arrestin2-biased ligands. Mol Pharmacol. 2012;82:1174–1182.
   PubMed Web of Science ®Google Scholar
• Baltos J-A, Paoletta S, Nguyen ATN, et al. Structure-activity analysis of biased agonism at the human adenosine A3 receptor. Mol Pharamol. 2016;90:11–12.
   Web of Science ®Google Scholar
• McPherson J, Rivero G, Baptist M, et al. μ-opioid receptors: correlation of agonist efficacy for signalling with ability to activate internalization. Mol Pharmacol. 2010;78:756–766.
   PubMed Web of Science ®Google Scholar
• Nickolls SA, Waterfield A, Williams RE, et al. Understanding the effect of different assay formats on agonist parameters: a study using the µ-opioid receptor. J Biomol Screen. 2011;16:706–716.
   PubMedGoogle Scholar
• Thompson GL, Lane JR, Coudrat T, et al. Biased agonism of endogenous opioid peptides at the μ-opioid receptor. Mol Pharmacol. 2015;88:35–346.
   Web of Science ®Google Scholar
• D’Antona AM, Ahn KH, Kendall DA. Mutations of CB1 T219 produce active and inactive receptor forms: correlations with ligand affinity, receptor stability and cellular localization. Biocehm. 2006;45:5606–5617.
   PubMed Web of Science ®Google Scholar
• Belmer A, Doly S, Setola V, et al. Role of N-terminal region in G protein-coupled receptor functions: negative modulation revealed by 5-HT2B receptor polymorphisms. Mol Pharmacol. 2014;85:127–138.
   PubMed Web of Science ®Google Scholar
• Tschammer N, Bollinger S, Kenakin T, et al. Histidine 6.55 is a major determinant of ligand-biased signaling in dopamine D2L receptor. Mol Pharmacol. 2011;79(3):575–585.
   PubMed Web of Science ®Google Scholar
• Gregory KJ, Sexton PM, Tobin AB, et al. Stimulus bias provides evidence for conformational constraints in the structure of a G protein-coupled receptor. J Biol Chem. 2012;287:37066–37077.
   PubMed Web of Science ®Google Scholar
• Kenakin TP. The relative contribution of affinity and efficacy to agonist activity: organ selectivity of noradrenaline and oxymetazoline. Br J Pharmacol. 1984;81:131–141.
   PubMed Web of Science ®Google Scholar
• Just S, Illing S, Trester-Zedlitz M, et al. Differentiation of opioid drug effects by hierarchical multi-site phosphorylation. Mol Pharmacol. 2013;83:633–639.
   PubMed Web of Science ®Google Scholar
• Quoyera J, Janz JM, Luoc J, et al. Pepducin targeting the C-X-C chemokine receptor type 4 acts as a biased agonist favoring activation of the inhibitory G protein. Proc Natl Acad Sci USA. 2013;110:E5088–E5097.
   Google Scholar
• Maillet EL, Pellegrini N, Valant C, et al. A novel, conformation-specific allosteric inhibitor of the tachykinin NK2 receptor (NK2R) with functionally selective properties. Faseb J. 2007;21:2124–2134.
   PubMed Web of Science ®Google Scholar
• Mathiesen JM, Ulven T, Martini L, et al. Identification of indole derivatives exclusively interfering with a G protein independent signaling pathway of the prostaglandin D2 receptor CRTH2. Mol Pharmacol. 2005;68:393–402.
   PubMed Web of Science ®Google Scholar
• Bradley SJ, Langmead CJ, Watson JM, et al. Quantitative analysis reveals multiple mechanisms of allosteric modulation of the mGlu5 receptor in rat astroglia. Mol Pharmacol. 2011;79:874–885.
   PubMed Web of Science ®Google Scholar
• Koole C, Wootten D, Simms J, et al. Allosteric ligands of the glucagon-like peptide 1 receptor (GLP-1R) differentially modulate endogenous and exogenous peptide responses in a pathway-selective manner: implications for drug screening. Mol Pharmacol. 2010;78:456–465.
   PubMed Web of Science ®Google Scholar
• Cook AE, Mistry SN, Gregory KJ, et al. Biased allosteric modulation at the CaS receptor engendered by structurally diverse calcimimetics. Br J Pharmacol. 2015;172:185–200.
   PubMed Web of Science ®Google Scholar
• Davey AE, Leach K, Valant C, et al. Positive and negative allosteric modulators promote biased signaling at the calcium-sensing receptor. Endocrinology. 2012;153:1232–1241.
   PubMed Web of Science ®Google Scholar